ArticleJournal of translational medicine2025
5T chemical exchange saturation transfer imaging improves glioma grading and genotyping prediction: a supplement to 3T diffusion and perfusion MRI.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
background and purposeAccurate grading and genotyping of gliomas are critical for tailoring personalized therapeutic strategies and predicting patient outcomes. This study investigates the potential of 5T glutamate chemical exchange saturation transfer (GluCEST) imaging in differentiating glioma grades and predicting pivotal molecular biomarker status.
methodsWe first validated the specificity of GluCEST signals to glutamate via phantom studies, then quantified potential interference from other metabolites. Thirty-four newly diagnosed glioma patients underwent preoperative 5T GluCEST imaging. The correlation between GluCEST values and the Ki-67 labeling index (LI) was analyzed using Spearman’s rank correlation. Furthermore, the capability of GluCEST values to predict glioma grade and genotype was assessed using receiver operating characteristic (ROC) curves and the area under the curve (AUC) metrics. These results were compared to advanced 3T MRI techniques, including relative cerebral blood volume (rCBV), apparent diffusion coefficient (ADC), and fractional anisotropy (FA).
resultsGluCEST signals were predominantly driven by glutamate and exhibited a significant positive correlation with phantom glutamate concentration. A strong correlation was also observed between GluCEST values and the Ki-67 LI (r = 0.565, P < 0.001). Notably, GluCEST imaging demonstrated high diagnostic performance in distinguishing low-grade gliomas (LGG) from high-grade gliomas (HGG) (AUC = 0.90, P < 0.001), as well as in predicting IDH mutation status (AUC = 0.88, P < 0.001) and 1p/19q codeletion status (AUC = 0.87, P < 0.001). By contrast, rCBV and ADC only showed moderate potential in identifying MGMT methylation (AUC = 0.73, P = 0.018) and EGFR amplification (AUC = 0.69, P = 0.049), respectively.
conclusionsIn conclusion, 5T GluCEST imaging provides complementary metabolic information to 3T MRI, showing strong potential as a reliable non-invasive tool for differentiating LGG from HGG and for predicting IDH mutation and 1p/19q codeletion status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.